Skip to Content

Orencia (abatacept) Disease Interactions

There are 5 disease interactions with Orencia (abatacept):


Abatacept (applies to Orencia) hepatitis B

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Abatacept, as other antirheumatic therapies have been associated with hepatitis B reactivation. Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with abatacept. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.


Abatacept (applies to Orencia) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

There have been reports of serious infections, including sepsis and pneumonia in patients receiving abatacept. Caution and close monitoring is recommended when considering the use of abatacept in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections. Administration of abatacept should be discontinued if a patient develops a serious infection.


Abatacept (applies to Orencia) COPD

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

In studies, patients with chronic obstructive pulmonary disease (COPD) treated with abatacept developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, dyspnea and pneumonia. Caution should be exercised in patients with RA and COPD being treated with abatacept such patients should be monitored for worsening of their respiratory status.


Abatacept (applies to Orencia) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Caution should be taken when prescribing abatacept for intravenous administration to diabetic patients as the intravenous formulation of abatacept contains maltose which can give falsely elevated blood glucose readings with certain blood glucose monitors on the day of abatacept infusion. If a patient is using such a monitor, advise the patient to discuss with their healthcare professional methods that do not react with maltose, such as using a different way to monitor your blood sugar levels.


Abatacept (applies to Orencia) tuberculosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Latent, Tuberculosis -- Active

Prior to initiating abatacept, patients should be screened for latent tuberculosis infection with a tuberculin skin test. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with abatacept. Caution should be taken when prescribing abatacept to these patients as this agent has not been studied in patients with a positive tuberculosis screen, and the safety of abatacept in individuals with latent tuberculosis infection is unknown. Anti-tuberculosis therapy should also be considered prior to initiation of abatacept in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Tuberculosis should be strongly considered in patients who develop a new infection during abatacept treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Orencia (abatacept) drug interactions

There are 111 drug interactions with Orencia (abatacept)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.